Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Year: 2020
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Maria Lia Palomba, Leo I. Gordon, Tanya Siddiqi, Jeremy S. Abramson, Manali Kamdar, Matthew A. Lunning, David G. Maloney, Charalambos Andreadis, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Scott R. Solomon, Thalia Farazi, Jacob Garcia, Christine Dehner, Ken Ogasawara, Jie Gao, Michael Wang
Institutions: Memorial Sloan Kettering Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, City Of Hope National Medical Center, Massachusetts General Hospital, University of Colorado Cancer Center, University of Nebraska Medical Center, Fred Hutch Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Beth Israel Deaconess Medical Center, Harvard University, Levine Cancer Institute, University of Alabama at Birmingham, Northside Hospital, Bristol-Myers Squibb (United States), Juno Therapeutics (United States), The University of Texas MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3095832065